Dako to Develop Companion Diagnostic Test for Amgen Cancer Drug Candidates

Dako has announced that it has entered into a new collaboration agreement with Amgen Inc. on the development of a companion diagnostic test for an Amgen cancer drug candidate in clinical development. The announcement follows Dakos announcement in January 2012 of a collaboration with Amgen Inc., to introduce a new business model supporting concurrent development of drug and diagnostics for a rare but deadly cancer.

“It is Dako’s mission to fight cancer. Hence, we are pleased to be chosen as Amgen’s partner once again for the development of companion diagnostics linked to Amgen’s investigational targeted therapies,” says Lars Holmkvist, Dako’s chief executive officer.

“This new collaboration with Amgen underlines Dako’s commitment to advance personalized medicine in cancer treatment as the selection of patients most likely to benefit from a specific treatment will increase the probability of therapeutic success for cancer patients suffering," Lars Holmkvist adds.

The news comes shortly after several pharmDxT^M collaborative agreements announced by Dako.